![]() |
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CARDIOVASCULAR
Department Physiology and Pharmacology (S.J., V.R., A.Z., M.K.), University of Western Ontario, London, Ontario, Canada; and The Institute of Cardiovascular Sciences (D.B., L.A.K.), St. Boniface General Hospital Research Centre, Winnipeg, Manitoba, Canada
Although inhibition of Na+/H+ exchanger isoform 1 (NHE-1) reduces cardiomyocyte hypertrophy, the mechanisms underlying this effect are not known. Recent evidence suggests that this may be associated with improved mitochondrial function. To understand the mechanistic bases for mitochondrial involvement in the antihypertrophic effect of NHE-1 inhibition, we examined the effect of the NHE-1-specific inhibitor N-[2-methyl-4,5-bis(methylsulphonyl)-benzoyl]-guanidine, hydrochloride (EMD, EMD87580; 5 µM) on the hypertrophic phenotype, mitogen-activated protein kinase (MAPK) activity, mitochondrial membrane potential (
m), permeability transition (MPT) pore opening, and superoxide generation in phenylephrine (PE)-treated neonatal rat cardiomyocytes. EMD significantly suppressed markers of cell hypertrophy, including cell surface area and gene expression of atrial natriuretic peptide and
-skeletal actin. EMD inhibited the PE-induced MPT pore opening, prevented the loss in 
m, and attenuated superoxide generation induced by PE. Moreover, the activation of p38 MAPK (p38) and extracellular signal-regulated kinase (ERK) 1/2 MAPKs induced by PE was significantly attenuated in the presence of EMD as well as the antioxidant catalase. To examine the role of MPT and mitochondrial Ca2+ uniport in parallel with EMD, the effects of cyclosporin A (0.2 µM) and ruthenium red (10 µM) were evaluated. Both agents significantly attenuated PE-induced hypertrophy and inhibited both mitochondrial dysfunction and p38 and ERK1/2 MAPK activation. Our results suggest a novel mechanism for attenuation of the hypertrophic phenotype by NHE-1 inhibition that is mediated by a reduction in PE-induced MAPK activation and superoxide production secondary to improved mitochondrial integrity.
Address correspondence to: Dr. Morris Karmazyn, Department of Physiology and Pharmacology, University of Western Ontario, London, ON, N6A 5C1, Canada. E-mail: morris.karmazyn{at}schulich.uwo.ca
This article has been cited by other articles:
![]() |
C. D. Garciarena, C. I. Caldiz, M. V. Correa, G. R. Schinella, S. M. Mosca, G. E. Chiappe de Cingolani, H. E. Cingolani, and I. L. Ennis Na+/H+ exchanger-1 inhibitors decrease myocardial superoxide production via direct mitochondrial action J Appl Physiol, December 1, 2008; 105(6): 1706 - 1713. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. L. Garcia-Cazarin, J. L. Smith, D. K. St. Clair, and M. T. Piascik The {alpha}1D-Adrenergic Receptor Induces Vascular Smooth Muscle Apoptosis via a p53-Dependent Mechanism Mol. Pharmacol., October 1, 2008; 74(4): 1000 - 1007. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Yu, D. A. Quinn, H. G. Garg, and C. A. Hales Deficiency of the NHE1 Gene Prevents Hypoxia-induced Pulmonary Hypertension and Vascular Remodeling Am. J. Respir. Crit. Care Med., June 1, 2008; 177(11): 1276 - 1284. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Javadov, A. Choi, V. Rajapurohitam, A. Zeidan, A. G. Basnakian, and M. Karmazyn NHE-1 inhibition-induced cardioprotection against ischaemia/reperfusion is associated with attenuation of the mitochondrial permeability transition Cardiovasc Res, January 15, 2008; 77(2): 416 - 424. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. E. Cingolani and I. L. Ennis Sodium-Hydrogen Exchanger, Cardiac Overload, and Myocardial Hypertrophy Circulation, March 6, 2007; 115(9): 1090 - 1100. [Full Text] [PDF] |
||||